Corneal Neovascularization
24
2
2
11
Key Insights
Highlights
Success Rate
79% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.5%
3 terminated out of 24 trials
78.6%
-7.9% vs benchmark
4%
1 trials in Phase 3/4
64%
7 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (24)
Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.
Corneal Crosslinking for Treatment of Corneal Neovascularization
Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.
Topical Avastin for Treatment of Corneal Neovascularization
The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization
Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment
A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization
Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization
Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
Treatment of Corneal Neovascularization With Topical Pazopanib
Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
Topical IL-1-Ra for Treatment of Corneal Neovascularization
Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions
Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
Corneal Thinning During Topical Bevacizumab Therapy
Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization
Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization